59856-06-3

Basic information

• Product Name: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE
• Synonyms: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE;AKOS 91915;5-ACETAMIDOINDANE;n-2,3-dihydro-1h-inden-5-ylacetamide;N-(2,3-dihydro-1H-inden-6-yl)acetamide;N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE(WXG01310)
• CAS NO: 59856-06-3
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175.23
• Product Categories: Amines;Fused Ring Systems
• Mol File: 59856-06-3.mol

Chemical Properties

• Melting Point: 106 °C
• Boiling Point: 357.1 °C at 760 mmHg
• Flash Point: 210.8 °C
• Appearance: /
• Density: 1.155 g/cm³
• Vapor Pressure: 2.8E-05mmHg at 25°C
• Refractive Index: 1.611
• PKA: 15.13±0.20(Predicted)
• CAS DataBase Reference: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE(59856-06-3)
• EPA Substance Registry System: N1-(2,3-DIHYDRO-1H-INDEN-5-YL)ACETAMIDE(59856-06-3)

Safety Data

• Hazardous Substances Data: 59856-06-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N1-(2,3-Dihydro-1H-inden-5-yl)acetamide is used as a potential drug molecule for its antifungal and anticancer properties, making it a candidate for the development of new therapeutic agents.
Used in Synthesis of Heterocyclic Compounds:
In the field of organic chemistry, N1-(2,3-Dihydro-1H-inden-5-yl)acetamide serves as a building block for the synthesis of various heterocyclic compounds, contributing to the creation of novel chemical entities with potential applications in medicine and other fields.
Used in Precursor Chemistry:
As a precursor, N1-(2,3-Dihydro-1H-inden-5-yl)acetamide is utilized in the synthesis of other bioactive compounds, highlighting its versatility and importance in the development of pharmaceuticals and related chemical products.

InChI:InChI=1/C11H13NO/c1-8(13)12-11-6-5-9-3-2-4-10(9)7-11/h5-7H,2-4H2,1H3,(H,12,13)

Upstream product

• 24425-40-9 indan-5-amine 
• 64-19-7 acetic acid 
• 75-36-5 acetyl chloride 
• 18312-45-3 propan-2-one O-acetyl oxime 
• 2620-44-2 5-nitro-1,3-benzodioxole 
• 7436-07-9 5-nitroindane 
• 36795-33-2 1-(indan-5-yl)ethanone oxime 
• 98-09-9 benzenesulfonyl chloride 
• 119273-81-3 6-nitro-2,3-dihydro-1H-inden-1-ol 
• 41734-55-8 5-nitro-1H-indene 
• 108-24-7 acetic anhydride 

Downstream Products

• 429682-68-8 N-(4-bromo-1-oxo-2,3-dihydro-1H-inden-5-yl)acetamide 
• 1025942-01-1 C₁₇H₁₅F₂NO₅S₃ 
• 1028259-13-3 C₁₇H₁₆F₂N₂O₅S₂ 
• 1027952-32-4 C₁₈H₁₇NO₇S₃ 
• 1026588-02-2 C₁₇H₁₆FNO₅S₃ 
• 1026743-88-3 C₁₈H₁₉NO₆S₃ 
• 1027483-80-2 C₁₈H₁₉NO₆S₃ 
• 1027313-32-1 C₂₀H₂₃NO₅S₃ 
• 1027504-89-7 C₁₇H₁₆FNO₅S₃ 
• 1027402-88-5 C₁₉H₂₁NO₅S₃ 
• 1026374-84-4 C₁₇H₂₃NO₅S₃ 

Relevant articles and documents

Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity

IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases. As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders. We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4. Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models. Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors. We identified potent molecule 19 that achieves robust in vivo inhibition of cytokines relevant to human disease.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (0), Formula (I), and Formula (II) and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

no abstract published

Synthesis and biological evaluation of 2-aryliminopyrrolidines as selective ligands for I1 imidazoline receptors: Discovery of new sympatho-inhibitory hypotensive agents with potential beneficial effects in metabolic syndrome

New 2-aryliminopyrrolidines (1-18) were synthesized and tested for their binding properties on I1 imidazoline receptors vs α2-adrenergic receptors and their blood pressure effects after both systemic and intracerebral administrations

BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME

The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereo

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kirl.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

Synthesis of bromoaminoindane and bromoaminoindanone derivatives

The bromination reactions of 5-aminoindane, 5-acetamidoindane, and 5-acetamidoindan-1-one were investigated using NBS, molecular bromine and photobromination, and the optimum reaction conditions were presented. The reaction of 5-aminoindane with glacial acetic acid at reflux temperature resulted in the formation of 5-acetamidoindane in high yield. 5-Acetamidoindan-1-one was generated by the reaction of 5-acetamidoindane with CrO3 in acetic acid. Selective bromination at C-6 position of 5-acetamidoindane was achieved by treatment of title compound with bromine in acetic acid and thus afforded 5-acetamido-6-bromoindane. Further bromination reactions of bromoindanones were achieved in various reaction conditions.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir 1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.